SciSparc (SPRC)
Develops cannabinoid drug candidates and sells Wellution hemp and personal-care products through Amazon.
Something off on this page? Send us feedback.
Develops CannAmide™-combined cannabinoid candidates through NeuroThera and sells Wellution hemp, supplement, beauty, and hair products via Amazon. Revenue comes from online sales, while drug development depends on clinical progress, regulatory approval, outside partners, and financing.
Pairs THC or non-psychoactive CBD with its CannAmide™ formulation in clinical candidates for Tourette syndrome, agitation associated with Alzheimer’s disease, and pediatric autism spectrum disorder. The drug portfolio sits principally within separately traded NeuroThera Labs, while SCI-160 is licensed to Polyrizon for milestones and royalties.
Generates its reported sales through Wellution™, an Amazon-based range of hemp, supplement, beauty, and hair-treatment products manufactured in the United States. It also acquired the MUSE™ endoscopy IP for a reflux-treatment device and is evaluating agentic-AI opportunities; neither initiative has a documented revenue stream.
Operates from Tel Aviv with clinical activity across Israel, Germany, and the United States, relying on contract research and manufacturing parties. Amazon FBA supplies the marketplace, fulfillment, order settlement, and much of the data infrastructure for revenue-producing sales.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Dec 31, 2025Cash & short-term investments $4.6M · Total debt $366.0K · Total assets $7.6M · Shareholders' equity $4.2M
- Revenue
- $395.0K
- Operating income
- $402.0K
- Net income
- −$2.9M
No dividends on record.
| Institutions3 holders · as of Mar 31, 2026 | 5.67% | 3.3K ADS | |
| Insiders9 holders · as of Jul 13, 2026 | 8.14% | 4.7K ADS | |
| Otherremainder | 86.19% | 49.9K ADS |
57.8K ADS (1 ADS = 12 ordinary shares) as of Aug 21, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count is from the company's Dec 2023 annual report; nothing newer is on file here.
A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
UBS Group AGInstitution | 5.44% | 3,146 ADS | 13Fas of Mar 31, 2026 |
Oz AdlerInsiderofficer: CEO and CFO | 1.59% | 11,058 ordinary | Form 4filed Mar 18, 2026 ↗ |
Amitay WeissInsiderdirector | 1.59% | 11,058 ordinary | Form 4filed Mar 18, 2026 ↗ |
Itschak ShremInsiderdirector | 1.53% | 10,596 ordinary | Form 4filed Jun 3, 2026 ↗ |
Adi Zuloff-ShaniInsiderofficer: Chief Technology Officer | 0.80% | 5,528 ordinary | Form 4filed Mar 18, 2026 ↗ |
| See all 17 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 1, 2026 | Itschak Shrem | director | −462 | $10.00 |
- Direxion Daily CSI China Internet Index Bull 2X ETF
Hemp gummies, oils, and topicals vie for online wellness buyers.
- Johnson & Johnson
LINX is an established procedural alternative for GERD treatment.
- AbbVie
Marinol supplies established oral THC for cannabinoid therapy.
- Jazz Pharmaceuticals
Epidiolex anchors a scaled prescription-CBD franchise.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| SciSparc | $5.76 | −1.37% | $338.4K | — | — | 0.4 | −15.2% |
| Direxion Daily CSI China Internet Index Bull 2X ETF | $19.78 | −3.10% | $153.4M | — | — | — | — |
| Johnson & Johnson | $275.01 | −0.08% | $663.23B | 31.9 | 23.1 | 6.8 | +6.6% |
| AbbVie | $261.51 | −0.08% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| Jazz Pharmaceuticals | $246.83 | +0.55% | $15.43B | 16.8 | 9.7 | 3.4 | +15.6% |
| Median | 31.9 | 17.2 | 6.8 | +10.2% |